What is Enzo Biochem, Inc. (ENZB)?

Enzo Biochem, Inc. (ENZB) is a stock in the Healthcare sector, Medical - Diagnostics & Research industry. View full analysis on Stocks360.

What is the current price of ENZB?

The current price of ENZB is $0.70. Prices are updated in real time on Stocks360.

What is ENZB's price-to-earnings (PE) ratio?

ENZB's trailing twelve-month PE ratio is -1.37, based on current price and earnings per share data available on Stocks360.

What is ENZB's market capitalization?

ENZB's market capitalization is $36,587,801.00, placing it in the small-cap tier.

Does ENZB pay a dividend?

Yes. ENZB has a trailing twelve-month dividend yield of 0.14%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Enzo Biochem, Inc. (ENZB)

Stock analysis · OTC · Healthcare · Medical - Diagnostics & Research

$0.70

Market Cap

$36.59M

PE (TTM)

-1.37

EPS (TTM)

N/A

Dividend Yield

14.31%

Beta

1.17

Day Range

$0.70 – $0.70

52-wk Range

$0.25 – $1.19

Avg Volume

N/A

Volume

149.65K

Enzo Biochem, Inc. (ENZB) is a publicly traded company in the Healthcare sector. Latest price: $0.70. Market cap $36.59M. Trailing PE -1.37. Dividend yield 14.31%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Oct 15, 2019

EPS $-0.11 vs est. $-0.14

Beat by $0.03

Proprietary Signals

Signal snapshot temporarily unavailable.

About Enzo Biochem, Inc.

Enzo Biochem, Inc. operates as an integrated entity encompassing diagnostics, clinical laboratory services, and life sciences. The company is dedicated to developing, manufacturing, and commercializing diagnostic and research products, fundamentally rooted in genetic engineering, biotechnology, and molecular biology. Its operations are organized into three primary segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products division focuses on creating, producing, and distributing essential products and tools for clients engaged in clinical research, pharmaceutical development, and broader bioscience investigations. Its extensive portfolio comprises proteins, antibodies, peptides, small molecules, labeling probes, dyes, and various kits. These offerings empower life science researchers in areas such as target identification and validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also serves scientific experts researching a wide array of health issues, including cancer, cardiovascular disorders, neurological diseases, diabetes and obesi…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.37×
P/S (TTM)	1.15×
P/B	0.63×
PEG	0.00×
P/FCF (TTM)	-1.37×
EV / EBITDA	1.47×
EV / Sales	-0.38×
Earnings Yield	-73.31%
Free Cash Flow Yield	-73.26%
Dividend Yield	14.31%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$12.27M
Net Income (TTM)	-$26.82M
Free Cash Flow (TTM)	-$26.61M
Net Debt	-$48.86M
Working Capital	$45.24M
Gross Margin	45.86%
Operating Margin	-30.77%
Net Margin	-81.73%
Return on Equity	-38.76%
Return on Invested Capital	-15.86%